Journal of Clinical Densitometry
Volume 13, Issue 2 , Pages 190-196 , April 2010

Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1

  • Stergios A. Polyzos

      Affiliations

    • Department of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece
    • Corresponding Author InformationAddress correspondence to: Stergios Alexandros Polyzos, MD, MSc, Endocrinologist, 13 Simou Lianidi, 551 34 Thessaloniki, Greece.
    • ,
  • Athanasios D. Anastasilakis

      Affiliations

    • Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece
    • ,
  • Ioannis Litsas

      Affiliations

    • Department of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Michail Sapranidis

      Affiliations

    • Department of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Zoe Efstathiadou

      Affiliations

    • Department of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Marina Kita

      Affiliations

    • Department of Endocrinology, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Georgios Arsos

      Affiliations

    • Department of Nuclear Medicine, Aristotle University, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Efstratios Moralidis

      Affiliations

    • Department of Nuclear Medicine, Aristotle University, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Efthimia Zafeiriadou

      Affiliations

    • Department of Radiology, Ippokration General Hospital, Thessaloniki, Greece
    • ,
  • Athanasios Papatheodorou

      Affiliations

    • Department of Medical Research, 251 General Airforce Hospital, Athens, Greece
    • ,
  • Evangelos Terpos

      Affiliations

    • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Received 6 November 2009 ,Revised 3 January 2010 ,Accepted 10 January 2010.

References 

  1. Polyzos SA, Anastasilakis AD, Terpos E. Paget's disease of bone: emphasis on treatment with zoledronic acid. Expert Rev Endocrinol Metabolism. 2009;4:424–434
  2. Pande KC, Bernard J, McCloskey EV, et al. Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone. Bone. 2000;26:525–528
  3. Haugeberg G. Imaging of metabolic bone diseases. Best Pract Res Clin Rheumatol. 2008;22:1127–1139
  4. Cherian RA, Haddaway MJ, Davie MW, et al. Effect of Paget's disease of bone on areal lumbar spine bone mineral density measured by DXA, and density of cortical and trabecular bone measured by quantitative CT. Br J Radiol. 2000;73:720–726
  5. Nuti R, Righi G, Turchetti V, et al. Total body and regional bone mineral analysis by dual-photon absorptiometry in Paget's disease of bone. Bone Miner. 1988;3:359–367
  6. Whitehouse RW. Paget's disease of bone. Semin Musculoskelet Radiol. 2002;6:313–322
  7. Moayyeri A, Kaptoge S, Dalzell N, et al. The effect of including quantitative heel ultrasound in models for estimation of 10-year absolute risk of fracture. Bone. 2009;45:180–184
  8. Anastasilakis AD, Polyzos SA, Avramidis A, et al. 2010 The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf). DOI: 10.1111/j.1365-2265.2009.03728.x. Epub ahead of print.
  9. Voskaridou E, Christoulas D, Xirakia C, et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 2009;94:725–728
  10. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol. 2008;80:490–494
  11. Naot D, Bava U, Matthews B, et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res. 2007;22:298–309
  12. Polyzos SA, Anastasilakis AD, Efstathiadou Z, et al. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone. Horm Metab Res. 2009;41:846–850
  13. Marshall MJ, Evans SF, Sharp CA, et al. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin Biochem. 2009;42:965–969
  14. Devogelaer JP, Bergmann P, Body JJ, et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int. 2008;19:1109–1117
  15. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898–908
  16. Patel S, Pearson D, Bhallah A, et al. Changes in bone mineral density in patients with Paget's disease treated with risedronate. Ann Rheum Dis. 1997;56:405–409
  17. Gutteridge DH, Retallack RW, Ward LC, et al. Bone density changes in Paget's disease 2 years after iv pamidronate: profound, sustained increases in pagetic bone with severity-related loss in forearm nonpagetic cortical bone. Bone. 2003;32:56–61
  18. Laroche M, Delpech B, Bernard J, et al. Measurement of bone mineral density by dual X-ray absorptiometry in Paget's disease before and after pamidronate treatment. Calcif Tissue Int. 1999;65:188–191
  19. Stewart GO, Gutteridge DH, Price RI, et al. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. Bone. 1999;24:139–144
  20. Price RI, Gutteridge DH, Stuckey BG, et al. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium. J Bone Miner Res. 1993;8:209–217
  21. Colina M, La CR, De LF, Trotta F. Paget's disease of bone: a review. Rheumatol Int. 2008;28:1069–1075
  22. Avramidis A, Polyzos SA, Moralidis E, et al. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab. 2008;26:635–641
  23. Polyzos SA, Anastasilakis AD, Terpos E. Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support Care Cancer. 2009;17:1329–1330
  24. Khan SA, McCloskey EV, Eyres KS, et al. Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res. 1996;11:178–182
  25. Eastell R, Black DM, Boonen S, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009;94:3215–3225
  26. Yang NP, Lin T, Wang CS, Chou P. Community-based survey of low quantitative ultrasound values of calcaneus in Taiwan. J Clin Densitom. 2003;6:131–141
  27. Gasser JA, Ingold P, Venturiere A, et al. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res. 2008;23:544–551
  28. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone. 2004;35:224–230
  29. Polyzos SA, Anastasilakis AD, Efstathiadou Z, et al. 2009 Serum homocysteine, folate and vitamin B(12) in patients with Paget's disease of bone: the effect of zoledronic acid. J Bone Miner Metab. DOI: 10.1007/s00774-009-0131-1 Epub ahead of print.

PII: S1094-6950(10)00007-7

doi: 10.1016/j.jocd.2010.01.006

Journal of Clinical Densitometry
Volume 13, Issue 2 , Pages 190-196 , April 2010

Article Tools

* Image Usage & Resolution